Mutant Calreticulin-Specific Monoclonal Antibody INCA033989 Produces Molecular Responses That Correlate With Clinical Responses in Patients With Myelofibrosis (SOHO 2026) - Sep 1, 2026 - Abstract #MPN-556; Location: LEVEL 3, HALL B3; P1 | "Spleen and anemia responses were comparable regardless of co-occurring somatic mutations being present, suggesting that clonal complexity does not limit treatment response. Despite modest mutCALR VAF reduction via peripheral blood NGS, the observed rapid reduction of mutCALR HSPCs supports disease-modifying INCA033989 activity. ASXL1: ASXL transcriptional regulator 1, EZH2: enhancer of zeste 2 polycomb repressive complex 2 subunit, Fc: fragment crystallizable region, HSPCs: hematopoietic stem and progenitor cells, IgG1: immunoglobulin G1, mAb: monoclonal antibody, NGS: next-generation sequencing, TET2: tet methylcytosine dioxygenase 2, VAF: variant allele frequency."
Clinical • First-in-human • Essential Thrombocythemia • Myelofibrosis • Myeloproliferative Neoplasm • Oncology • ASXL1 • CALR • EZH2 • TET2
|
|
John Mascarenhas MD 1; Jyoti Nangalia PhD 2; Claire Harrison MDDM 3; Jason Gotlib MD 4; Chenwei Tian PhD 5; Betty Lamothe PhD 5; Tatiana Zinger PhD 5; Erin Crowgey PhD 5; Evan Braunstein MD PhD 5; Steffen Koschmieder MD 6
|